Dr. Graham Campbell worked in NHS mental health services for 15 years; eight of those years as a consultant psychiatrist on an inpatient ward in Brighton & Hove. He has a longstanding interest in psychotherapy, has an MSc in Neuroscience from Kings College London and trained with the Imperial College Psychedelic Research team to work as an assistant guide on the psilocybin vs escitalopram depression trial.He has helped to organise and facilitate psychedelic integration groups in Brighton since 2019 and has worked as an associate editor for a special edition of Frontiers in Psychiatry on the potential clinical application of psychedelics. He is a member of the Advisory Council with The Institute of Psychedelic Therapy (IPT) and chairs Academic Circle (journal club) groups for IPT members/affiliates.In 2020, he left the NHS to work full-time as the Study Psychiatrist for a trial investigating N,N-dimethyltryptamine (DMT) as a potential treatment for Major Depressive Disorder. This trial is a collaboration between Imperial College and Small Pharma Ltd and is being conducted at Hammersmith Medicines Research (HMR) in London. Phase I of the trial, with healthy volunteers, has been completed, with Phase IIa still underway.